streptococcus pneumoniae type strain atcc 33400  (ATCC)

Journal: Antibiotics

Article Title: TXA11114 : Discovery of an In Vivo Efficacious Efflux Pump Inhibitor (EPI) That Potentiates Levofloxacin Against Pseudomonas aeruginosa

doi: 10.3390/antibiotics15040346

Figure Lengend Snippet: P. aeruginosa ATCC 27853 outer- and inner-membrane permeabilization studies with TXA11114 . TXA11114 dose response effect on bacterial outer- and inner-membrane was determined. Polymyxin B was used as positive control. NCF hydrolysis ( A , B ) was used as read out for outer-membrane activity while inner-membrane activity was determined by measurement of PI fluorescence ( C ) using flow cytometry. Experiments were repeated three times to ensure reproducibility.

Article Snippet: Type strain P. aeruginosa ATCC 27853 cells were incubated with EtBr to allow for intracellular accumulation and treated with carbonyl cyanide 3-chlorophenylhydrazone (CCCP) to inhibit active efflux.

Techniques: Membrane, Positive Control, Activity Assay, Fluorescence, Flow Cytometry

Journal: Antibiotics

Article Title: TXA11114 : Discovery of an In Vivo Efficacious Efflux Pump Inhibitor (EPI) That Potentiates Levofloxacin Against Pseudomonas aeruginosa

doi: 10.3390/antibiotics15040346

Figure Lengend Snippet: Time killing kinetics of levofloxacin alone or in combination with different doses of TXA11114 against P. aeruginosa type strain ATCC 27853 ( A ) and clinical isolate AR-0232 ( B ). Data are presented as mean values with standard deviations derived from technical triplicates.

Article Snippet: Type strain P. aeruginosa ATCC 27853 cells were incubated with EtBr to allow for intracellular accumulation and treated with carbonyl cyanide 3-chlorophenylhydrazone (CCCP) to inhibit active efflux.

Techniques: Derivative Assay

Journal: Antibiotics

Article Title: TXA11114 : Discovery of an In Vivo Efficacious Efflux Pump Inhibitor (EPI) That Potentiates Levofloxacin Against Pseudomonas aeruginosa

doi: 10.3390/antibiotics15040346

Figure Lengend Snippet: In vivo efficacy in murine thigh and lung infection models. ( A ) Efficacy of TXA11114 /levofloxacin combination murine thigh infection model: In this model, mice were inoculated intramuscularly (IM) in the right thigh with 5.75 log 10 CFU of P. aeruginosa ATCC 27853. Pretreatment control was determined 6.08 log 10 CFU at 2 h (baseline). Then, 24 h after infection, the mean bacterial thigh titers reached 8.82 log 10 CFU at 24 h (untreated control), confirming successful colonization. Mice were treated 2 h after infection with vehicle, TXA11114 (fixed 30 mg/kg, IV, Q6H), levofloxacin alone (10, 15, and 20 mg/kg, SC, Q6H) or in combination for 24 h. CFU/thigh was determined at 24 h after infection. Relative changes in CFU with treatment to baseline were plotted. Five mice were used per group. Tukey’s multiple comparisons test was used after an ANOVA to determine which specific pairs of group means were statistically different. * p < 0.05; † p < 0.01 (vs. control). ( B ) In vivo efficacy of TXA11114 /levofloxacin in murine lung model. In the lung infection model, mice were inoculated intranasally with 4.83 log 10 CFU of P. aeruginosa ATCC 27853. Pretreatment bacterial load in lung was 4.59 log 10 CFU/lung determined 2 h. after infection (baseline). Bacterial load was increased to 8.89 log 10 CFU at 24 h post-infection in the untreated control set. Mice for each group were treated with vehicle, TXA11114 (30 mg/kg, IV, Q6H), levofloxacin alone (30 mg/kg, SC, Q6H) or in combination for 24 h. Post-treatment, bacterial lung burden was determined 24 h after infection and changes in bacterial counts are represented relative to baseline. Data are represented as the mean ± standard deviation (SD), within an experimental group. A p value < 0.05 was considered statistically significant. Five mice were used per group. Tukey’s multiple comparisons test was used after an ANOVA to determine which specific pairs of group means were statistically different.

Article Snippet: Type strain P. aeruginosa ATCC 27853 cells were incubated with EtBr to allow for intracellular accumulation and treated with carbonyl cyanide 3-chlorophenylhydrazone (CCCP) to inhibit active efflux.

Techniques: In Vivo, Infection, Control, Standard Deviation

Journal: bioRxiv

Article Title: TCA cycle entry point, growth variability and amino acid utilization in Alteromonas macleodii ATCC 27126

doi: 10.64898/2026.03.04.709670

Figure Lengend Snippet: From left to right: The growth (OD and cell count) of ATCC 27126 on various amino acids (blue background), in comparison with the pyruvate positive control and the equimolar positive control (green background), and the carbon free negative control (red background). The top row shows growth on plates, in comparison with the OD and cell counts in tubes (Lower three rows).

Article Snippet: Moreover, several of the catabolic pathways that are encoded in the genome of the type strain Alteromonas macleodii ATCC 27126 (henceforth ATCC 27126), appear incomplete, i.e. they lack homologs of enzymes known from other bacteria to participate in these pathways ( ).

Techniques: Cell Characterization, Comparison, Positive Control, Negative Control